PRECISION BIOLOGICS TO PRESENT AT IMMUNO 2024, LONDON, UK, APRIL 25 – 26, 2024
IMMUNO 2024, LONDON, UK, APRIL 25 - 26, 2024 Day 1: Track 1: Discovery & Development:...
25Apr
15Apr
Read more...
05Apr
American Association for Cancer Research (AACR) 2024 Annual Meeting, April 8, 2024, San Diego, CA, San Diego Convention Center
Precision Biologics will present recent scientific data at the American Association for Cancer Research (AACR)...
12Dec
Dr. Philip Arlen, CEO, to give two scientific talks in Tokyo, Japan, December 14th – 15th, 2023
Dr. Philip M. Arlen, President & CEO of Precision Biologics, Inc. will deliver a scientific...
24Nov
Dr. Massimo Fantini et al. of Precision Biologics publishes review article in Frontiers of Immunology
Natural killer (NK) cells are cellular components of the innate immune system that can recognize...
02Nov
Precision Biologics to present new data on NEO-201 at the Society for Immunotherapy of Cancer (SITC)
Precision Biologics presents new data from ongoing NEO-201 clinical trial at the Society for Immunotherapy...
05Oct
Precision Biologics Announces new US Patent on its lead asset, NEO-201
Precision Biologics Announces the United States Patent and Trademark Office (USPTO) has granted a Patent...
18Sep
Precision Biologics to give presentation at CICON 2023, Milan, Italy – shares new NEO-201 data from current Phase 2 Clinical Trial
Precision Biologics announces that Massimo Fantini PhD, our Director of Research and Development, will deliver...
13Apr
AACR 2023 – Poster presentation in person, Orlando, FL, Orange County Convention Center, Tuesday, April 18th, 2023
A poster will be presented in person at the American Association for Cancer Research (AACR)...
06Apr
Precision Biologics Announces Publication Of First-In-Human Phase 1 Clinical Trial With NEO-201
Precision Biologics, Inc. publishes data and analysis from recent First-In-Human Phase 1 Clinical Trial With...